Risultati e situazione finanziariaSalute - farmaceutica - biotech
Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
10/11/2026 07:00
AMFPubblicazione immediata
Lyon (France), November 10, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive five-year antibody persistence data for its single dose chikungunya vaccine IXCHIQ®. The results demonstrate durable antibody persistence across all age groups…
VALNEVA SE
Îlot Saint-Joseph, Bureaux Convergence, Bât. A,
12 ter Quai Perrache
69002 Lyon, France
Valneva Reports Sustained 94% Seroresponse Five Years After a
Single Dose of Chikungunya Vaccine IXCHIQ®
- 94% of participants maintained seroresponse five years after a single vaccination
- Comparable antibody persistence observed in older (65+) and younger adults
- Data further reinforce IXCHIQ®'s differentiated profile with durable antibody persistence against an unpredictable outbreak disease
Lyon (France), November 10, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive five-year antibody persistence data for its single dose chikungunya vaccine IXCHIQ®. The results demonstrate durable antibody persistence across all age groups evaluated and are consistent with previously reported persistence results1,2,3,4. The results are in line with Valneva’s expectations for this vaccine, further supporting IXCHIQ®'s differentiated profile and its potential to provide long-term protection following a single vaccination, similarly to other live-attenuated vaccines56. Among the 221 healthy adults who were evaluable at Year 5, 94% maintained neutralizing antibody titers well above the seroresponse threshold7 five years after the single-dose vaccination. Antibody persistence in older adults aged 65 years and above was comparable to that observed in younger adults aged 18 to 64 years, with similar geometric mean titers (GMTs) and seroresponse rates (SRRs).
Hanneke Schuitemaker, Ph.D., Chief Scientific Officer of Valneva, commented, “These fiveyear data further reinforce IXCHIQ®'s unique value proposition. For diseases such as chikungunya, where outbreaks are difficult to predict, durable immune persistence following a single dose represents a significant public health advantage. This is particularly important not only for travelers, but also for populations living in endemic regions, many of which are in lowand middle-income countries where access to healthcare and vaccination may be more limited.” Trial VLA1553-303 received funding support from the Coalition for Epidemic Preparedness Innovations (CEPI) and the European Union's Horizon Europe program. Under the study protocol, participants will continue to be followed for up to ten years after vaccination to further characterize the long-term durability of immune responses generated by IXCHIQ®.
Valneva is also continuing to generate real-world evidence for IXCHIQ® through several postmarketing studies and initiatives, including a Pilot Vaccination Strategy (PVS) in Brazil, the first 1 Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate - Valneva 2 Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - Valneva; McMahon et al., J TJ Travel Med. 2024 Mar 1;31(2):taad156.doi: 10.1093/jtm/taad156 3 Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - Valneva 4 Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ® - Valneva 5 Lindsey NP, Horiuchi KA, Fulton C, Panella AJ, Kosoy OI, Velez JO, Krow-Lucal ER, Fischer M, Staples JE. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers. J Travel Med. 2018 Jan 1;25(1):10.1093/jtm/tay108. doi: 10.1093/jtm/tay108. PMID: 30346562; PMCID: PMC7135922. 6 Kamal Desai, L. Coudeville, F. Bailleux, Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine, Vaccine, Volume 30, Issue 15, 2012, Pages 2510-2515, ISSN 0264-410X, ) 7 A neutralizing antibody titer of ≥150 determined by μPRNT50, i.e. the antibody level agreed with regulators as endpoint under the accelerated approval pathway.